New Blood Test Aims to Detect Liver Cirrhosis Early A new non-invasive blood test, CIRRHOClear, has been launched in Singapore to identify the risk of liver cirrhosis before symptoms manifest. Developed by biotechnology firm Mirxes and the National Cancer Centre Singapore (NCCS), the test is designed for individuals aged 40 and above who may be at higher risk due to conditions like fatty liver disease, chronic hepatitis, or alcohol-related liver issues.

How the Test Works

CIRRHOClear analyzes specific microRNA (miRNA) biomarkers found in a standard blood sample. When the liver experiences inflammation or damage, it releases abnormal levels of these molecules into the bloodstream. A proprietary algorithm then classifies a patient’s cirrhosis risk as high, intermediate, or low. In clinical validation studies, the test demonstrated an 89% accuracy rate in determining cirrhosis risk and a 95% accuracy rate in identifying those without the condition.

Addressing Screening Gaps

Current screening methods often face limitations; routine blood tests and ultrasounds lack sensitivity for early-stage scarring, while advanced imaging techniques are typically restricted to specialist centers. Furthermore, the gold standard—a liver biopsy—is invasive and carries risks, making it unsuitable for routine population screening. The development of CIRRHOClear was supported by the four-year ELEGANCE study, which involved 2,000 participants with liver disease. By enabling earlier detection, the test aims to help physicians intervene sooner, potentially slowing the progression of liver damage and preventing life-threatening complications such as liver failure and hepatocellular carcinoma, the most common form of liver cancer. The test is currently available at clinics and screening centers in Singapore, with future plans to expand to other countries.